The estimated Net Worth of Richard J. Gregory is at least 879 千$ dollars as of 18 November 2019. Richard Gregory owns over 10,806 units of Homology Medicines Inc stock worth over 10,050$ and over the last 9 years he sold FIXX stock worth over 641,997$. In addition, he makes 226,913$ as Independent Director at Homology Medicines Inc.
Sign up
Richard Gregory FIXX stock SEC Form 4 insiders trading
Richard has made over 8 trades of the Homology Medicines Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 10,806 units of FIXX stock worth 324$ on 18 November 2019.
The largest trade he's ever made was selling 36,643 units of Homology Medicines Inc stock on 22 February 2019 worth over 205,201$. On average, Richard trades about 6,497 units every 74 days since 2015. As of 18 November 2019 he still owns at least 10,806 units of Homology Medicines Inc stock.
You can see the complete history of Richard Gregory stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Gregory biography
Dr. Richard J. Gregory Ph.D. serves as Independent Director of the Company. Prior to his retirement, Dr. Gregory served as Executive Vice President and Chief Scientific Officer of ImmunoGen, Inc., a biotechnology company, from 2015 until August 2019. Prior to joining ImmunoGen, Inc., he spent 25 years at Genzyme Corporation, a biotechnology company, in roles of increasing responsibility, including Senior Vice President and Head of Research from 2003 until Genzyme Corporation’s acquisition by Sanofi in 2011, and Head of Research and Development for Genzyme from 2011 through 2014. Dr. Gregory serves as a director of ProMIS Neurosciences, Inc. Dr. Gregory received his B.A. in Science from Virginia Tech and holds a Ph.D. from the University of Massachusetts, Amherst, and completed his post-doctoral work at the Worcester Foundation for Experimental Biology.
What is the salary of Richard Gregory?
As the Independent Director of Homology Medicines Inc, the total compensation of Richard Gregory at Homology Medicines Inc is 226,913$. There are 10 executives at Homology Medicines Inc getting paid more, with Arthur Tzianabos having the highest compensation of 5,062,880$.
What's Richard Gregory's mailing address?
Richard's mailing address filed with the SEC is C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD, MA, 01730.
Insiders trading at Homology Medicines Inc
Over the last 7 years, insiders at Homology Medicines Inc have traded over 108,214,465$ worth of Homology Medicines Inc stock and bought 3,033,333 units worth 51,999,993$ . The most active insiders traders include Steven Gillis、James Edeerfield Management...、Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of 106,785$. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth 21,883$.
What does Homology Medicines Inc do?
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
What does Homology Medicines Inc's logo look like?
Complete history of Richard Gregory stock trades at Immunogen、Homology Medicines Inc
Homology Medicines Inc executives and stock owners
Homology Medicines Inc executives and other stock owners filed with the SEC include:
-
Arthur Tzianabos,
President, Chief Executive Officer, Director -
Tim Kelly,
Chief Technical Operations Officer -
Albert Seymour,
Chief Scientific Officer -
W. Bradford Smith,
Chief Financial Officer, Treasurer and Secretary -
Dr. Arthur O. Tzianabos Ph.D.,
Pres, CEO & Director -
Dr. Albert Seymour Ph.D.,
Chief Scientific Officer -
W. Bradford Smith CPA, M.B.A.,
CFO & Treasurer -
Alise Reicin,
Independent Director -
Kush Parmar,
Independent Director -
Mary Thistle,
Independent Director -
Richard Gregory,
Independent Director -
Matthew Patterson,
Independent Director -
Steven Gillis,
Independent Director -
Jeffrey Poulton,
Director -
Gabriel Cohn,
Chief Medical Officer -
Cara Mayfield,
Director of Corp. Communications -
Dr. Deborah Kinch Ph.D.,
Chief Devel. Officer -
Dr. Julie Jordan M.D.,
Sr. VP and Head of Clinical Devel. & Operations -
Michael Blum M.B.A.,
Chief Commercial Officer -
Dr. Gabriel M. Cohn M.B.A., M.D.,
Chief Medical Officer -
Melissa Gelormini,
VP of HR -
Theresa McNeely,
Chief Communications Officer & Patient Advocate -
Dr. Paul Alloway J.D., Ph.D.,
Chief Legal Officer & Sec. -
Timothy P. Kelly M.B.A.,
Chief Operating Officer -
Dr. Saswati Chatterjee Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Ventures Iv, L.P.5 Am Co In...,
-
Ventures Iv, L.P.5 Am Partn...,
-
Institutes For Bio Medical ...,
-
Ventures, Llcvv Manager Llc...,
-
Holdings (Private) Ltd Full...,
-
Cameron Wheeler,
Director -
Siyamak Rasty,
Chief Operating Officer -
James Edeerfield Management...,
-
James Edeerfield Management...,
-
Venture Fund Viii, L.P.Arch...,
-
Springs Capital Management ...,
-
Venture Fund Viii, L.P.Arch...,
-
Charles Jr Michaud,
See Remarks -
Paul Alloway,
See Remarks -
Michael Lee Blum,
Chief Commercial Officer -
Julie Jordan,
Chief Medical Officer